GlassScriptPhysician profile
Sathvika Velur
NPI 1932339413
$1,856.35
in general payments reported to CMS, 2019-2025
19 companies · $1,843 in 2025
The $1,843 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $13.51 · 2025: $1,843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,775 · Education: $81.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,775.33 |
| Education | $81.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $383.46 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Novo Nordisk INC | $210.25 | 2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $179.16 | 2025 | Minimed 780g |
| Insulet Corporation | $157.30 | 2025 | Omnipod |
| Abbott Laboratories | $133.74 | 2025 | Freestyle Libre 3 |
| Kyowa Kirin, INC. | $133.24 | 2025 | |
| Tandem Diabetes Care, INC. | $112.32 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $96.87 | 2025 | Isturisa |
| Neurocrine Biosciences, INC. | $82.35 | 2025 | |
| Corcept Therapeutics | $68.05 | 2025 | Korlym |
| Dexcom, INC. | $52.62 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $51.20 | 2025 | Mounjaro, Zepbound |
| Cequr Corporation | $44.70 | 2025 | Cequr Simplicity |
| Exact Sciences Corporation | $36.10 | 2025 | The Cologuard Plus Collection Kit |
| Sequel Med Tech, LLC | $34.71 | 2025 | Twiist |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $34.15 | 2025 | |
| Heartflow, INC. | $16.96 | 2025 | |
| Glaxosmithkline, LLC. | $15.14 | 2025 | Trelegy Ellipta |
| Amgen INC. | $14.03 | 2025 | Evenity, Prolia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sathvika Velur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.